Author | James J. Lee, MD, PhD


The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?

September 18, 2018

In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.

Personalized Medicine in the Adjuvant Chemotherapy of Stage II Colon Cancer-Are We There Yet?

August 15, 2013

Over the past few years, significant efforts have focused on developing and validating molecular biomarkers to better define the subset of patients with stage II disease who might derive benefit from adjuvant therapy.